{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:52:19Z","timestamp":1793159539387,"version":"4.5.0"},"reference-count":184,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.1021\/acs.molpharmaceut.4c01173","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:43:36Z","timestamp":1753440216000},"page":"5139-5164","source":"Crossref","is-referenced-by-count":8,"title":["Pharmaceutical Nitrosamines: A Comprehensive Review of Health Risks, Detection, Mitigation Strategies Supplemented with CYP450 Interactions as Molecular Simulations for Mechanistic Insight into Carcinogenicity"],"prefix":"10.1021","volume":"22","author":[{"given":"Kardile Punam","family":"Kashinath","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics","place":["Kolkata, India"]},{"name":"National Institute of Pharmaceutical Education and Research (NIPER)","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Samim","family":"Sardar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics","place":["Kolkata, India"]},{"name":"National Institute of Pharmaceutical Education and Research (NIPER)","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-2505","authenticated-orcid":true,"given":"Subhadeep","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology","place":["Kolkata, India"]},{"name":"National Institute of Pharmaceutical Education and Research","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, Mehrauli - Badarpur Road, Pushp Vihar Sector 03, New Delhi 110017, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-2925","authenticated-orcid":true,"given":"Santanu","family":"Kaity","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics","place":["Kolkata, India"]},{"name":"National Institute of Pharmaceutical Education and Research (NIPER)","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"ref1\/cit1","unstructured":"European Medicines Agency\n                      Sartan medicines: companies to review manufacturing\nprocesses to avoid presence of nitrosamine impurities\n                      . www.ema.europa.eu\/contact (accessed Apr 29, 2024)."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.1133"},{"key":"ref3\/cit3","author":"European Medicines Agency","journal-title":"EMA update on metformin diabetes medicines"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105355"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.162004"},{"key":"ref7\/cit7","unstructured":"Information Note Nitrosamine impurities\n                      . https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities (accessed Apr 29, 2024)."},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.782536"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.017"},{"key":"ref10\/cit10","unstructured":"European Medicines Agency\n                      Assessment and Control Of Dna Reactive (Mutagenic)\nImpurities In Pharmaceuticals To Limit Potential Carcinogenic Risk\nM7(R1) Current Step 4 version\n                      ; European Medicines\nAgency, 2017."},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1248\/jhs1956.35.307"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2003.08.005"},{"key":"ref13\/cit13","doi-asserted-by":"crossref","unstructured":"Byrn, S.; Stowell, J. Impurities in Drug Substances and Drug Products. In\n                      Validation of Active Pharmaceutical Ingredients\n                      , 2nd ed. CRC Press, 2001; pp 271\u2212292.","DOI":"10.1201\/b14415-10"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-023-03560-x"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1042\/bj1100039"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1218(96)90038-5"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(99)00022-6"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2007.06.032"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04068.x"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105403"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/2.12.1339"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.5530\/ijopp.13.1.1"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18189465"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026739"},{"key":"ref25\/cit25","volume":"31","author":"European Medicines Agency","year":"2019","journal-title":"EMA to review ranitidine medicines following detection of NDMA"},{"key":"ref26\/cit26","unstructured":"Information\nUpdate - Health Canada updates Canadians on its ongoing\nassessment of nitrosamine impurities in certain drugs\n                      . https:\/\/www.newswire.ca\/news-releases\/information-update-health-canada-updates-canadians-on-its-ongoing-assessment-of-nitrosamine-impurities-in-certain-drugs-857533601.html (accessed Apr 29, 2024)."},{"key":"ref27\/cit27","unstructured":"Update on N-nitrosamine\nimpurities\n                      , Sept, 2023. https:\/\/extranet.who.int\/prequal\/news\/update-n-nitrosamine-impurities (accessed Apr 29, 2024)."},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.31838\/ecb\/2023.12.si5.054"},{"key":"ref29\/cit29","unstructured":"Quality (chemistry and manufacturing) draft guidance: New\nDrug Submissions\nand Abbreviated New Drug Submissions - Canada\n                      . https:\/\/www.canada.ca\/en\/health-canada\/programs\/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices\/quality-draft-abbreviated-new-drug-submissions.html (accessed Apr 29, 2024)."},{"key":"ref30\/cit30","unstructured":"IARC Publications Some\n                      N\n                      -Nitroso Compounds. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans\/Some-Em-N-Em-Nitroso-Compounds-1978 (accessed Jul 26, 2023)."},{"key":"ref31\/cit31","series-title":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","volume-title":"Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1\u221242","author":"International Agency for Research on Cancer","year":"1987"},{"key":"ref32\/cit32","unstructured":"FDA announces voluntary\nrecall of several medicines containing valsartan\nfollowing detection of an impurity\n                      . https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity (accessed Jul 26, 2023)."},{"key":"ref33\/cit33","author":"FDA","journal-title":"FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm\u2019s already recalled products"},{"key":"ref34\/cit34","author":"FDA","journal-title":"FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall"},{"key":"ref35\/cit35","unstructured":"Information Note Nitrosamine\nimpurities\n                      . https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities (accessed Jul 26, 2023)."},{"key":"ref36\/cit36","unstructured":"LaboratoryTest, Ranitidine\n                      . https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/laboratory-tests-ranitidine (accessed Jul 27, 2023)."},{"key":"ref37\/cit37","author":"European Medicines Agency","journal-title":"Suspension of ranitidine medicines in the EU"},{"key":"ref38\/cit38","author":"FDA","journal-title":"FDA Requests Removal of All Ranitidine Products (Zantac) from the Market"},{"key":"ref39\/cit39","unstructured":"FDA Updates and Press Announcements\non Nitrosamines in Rifampin and\nRifapentine\n                      . https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentin (accessed Jul 27, 2023)."},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1021\/tx7003823"},{"key":"ref41\/cit41","first-page":"1","volume":"88","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2006","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1021\/tx700189c"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2021.115102.15195"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq121"},{"key":"ref45\/cit45","author":"FDA","journal-title":"Information about Nitrosamine Impurities in Medications"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.0c02774"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1021\/cr60209a001"},{"key":"ref48\/cit48","first-page":"24","author":"Food and Drug Administration","year":"2021","journal-title":"Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry (Revision 1)"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1021\/ja01580a009"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1039\/c19670000362"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1218(96)90038-5"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1021\/ja00120a006"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1002\/cber.19751080419"},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/54.2.465"},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1002\/anie.196808061"},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.12.010"},{"key":"ref57\/cit57","unstructured":"Wexler, P.; Anderson, B.; de Peyster, A.; Gad, S.; Kamrin, M; Locey, B.; Mehendale, H. M.; Pope, C.; Shugart, L.\n                      Encyclopedia of Toxicology\n                      ; Elsevier; Vol. 1, www.info.sciencedirect.com (accessed Jul 26, 2023)."},{"key":"ref58\/cit58","doi-asserted-by":"crossref","unstructured":"Adachi, M.; Saito, H.; Kobayashi, H.; Horie, Y.; Kato, S.; Yoshioka, M.; Ishii, H.\n                      Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido Background: The Chinese herbal dietary supplements Chaso\n                      , 2003. www.annals.org (accessed Jul 26, 2023).","DOI":"10.7326\/0003-4819-139-6-200309160-00012"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2004.07.013"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/18.3.587"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2019.01.074"},{"key":"ref62\/cit62","doi-asserted-by":"publisher","DOI":"10.1002\/jsscb.380170307"},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0246-9"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1002\/j.2050-0416.1986.tb04373.x"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1038\/247288a0"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00473-w"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00234"},{"key":"ref68\/cit68","unstructured":"European\nMedicines Agency\n                      Lessons learnt from\npresence of N-nitrosamine\nimpurities in sartan medicines\n                      . https:\/\/www.ema.europa.eu\/en\/news\/european-regulators-make-recommendations-drawing-lessons-learnt-presence-nitrosamines-sartan-medicines (accessed Jan 17, 2025)."},{"key":"ref69\/cit69","unstructured":"Mylan, A.V.\n                      Committee for Medicinal Products for Human Use (CHMP) Assessment report\n                      ; European Medicines Agency, 2019."},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.1021\/JA01642A029"},{"key":"ref71\/cit71","doi-asserted-by":"publisher","DOI":"10.1007\/BF00851216"},{"key":"ref72\/cit72","unstructured":"USEPA\n                      NDMA Fact Sheet\n                      ; USEPA, 2014; pp 1\u22127."},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1002\/cber.187500802203"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","unstructured":"Unsym.Dimethylhydrazine\nHydrochloride.\n                      Org. Synth.\n                      1936, 16, 2210.15227\/orgsyn.016.0022","DOI":"10.15227\/orgsyn.016.0022"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.1002\/cber.19771100531"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1002\/cber.191104401133"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.1021\/jo00953a031"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1021\/jo00964a010"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1021\/jo00896a016"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.1007\/BF00144269"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(91)90123-4"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1190"},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.4236\/jep.2020.119040"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs306"},{"key":"ref85\/cit85","unstructured":"National Research Council\n                      Aromatic Amines: An Assessment of the Biological\nand Environmental Effects\n                      ; National Research\nCouncil, 1981."},{"key":"ref86\/cit86","unstructured":"Rom, N.W.\n                      Environmental and Occupational Medicine\n                      , 4th ed. Lippincott Williams and Wilkins, 2007."},{"key":"ref87\/cit87","doi-asserted-by":"publisher","DOI":"10.3791\/56312"},{"key":"ref88\/cit88","doi-asserted-by":"publisher","DOI":"10.13005\/bbra\/3272"},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1788375"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.124102"},{"key":"ref91\/cit91","unstructured":"Safety evaluation challenges with nitrosamines\n                      . https:\/\/www.pharmalex.com\/thought-leadership\/blogs\/safety-evaluation-challenges-with-nitrosamines\/ (accessed Dec 7, 2024)."},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.53294\/ijfcpr.2023.3.1.0052"},{"key":"ref93\/cit93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.11.010"},{"key":"ref94\/cit94","unstructured":"Analytical challenges and the effective management of nitrosamines:\nThe evolving landscape of NDSRI analysis\n                      . https:\/\/event.on24.com\/wcc\/r\/4726830\/A662C0E67DB495062F01B5629A651E76?partnerref=E.24CMD.PB104.24009.01 (accessed Dec 7, 2024)."},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1002\/9783527678129.assep001"},{"key":"ref96\/cit96","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2013.04.016"},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2022.100037"},{"key":"ref98\/cit98","unstructured":"ACE HPLC columns\n                      . https:\/\/www.hplc.eu\/ace.htm (accessed Jul 29, 2023)."},{"key":"ref99\/cit99","unstructured":"Phenomenex UHPLC, HPLC,\nSPE, GC - Leader in Analytical Chemistry\nSolutions\n                      . https:\/\/www.phenomenex.com\/ (accessed Jul 29, 2023)."},{"key":"ref100\/cit100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.022"},{"key":"ref101\/cit101","doi-asserted-by":"publisher","DOI":"10.1039\/C4AY02967D"},{"key":"ref102\/cit102","unstructured":"FDA CDER\n                      Liquid Chromatography-High Resolution Mass Spectrometry\n(LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug\nSubstance and Drug Product\n                      . https:\/\/www.fda.gov\/media\/131868\/download (accessed Aug 27, 2024)."},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1021\/es061332s"},{"key":"ref104\/cit104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48344-5"},{"key":"ref105\/cit105","unstructured":"chem Jumpstations\n                      . https:\/\/www.agilent.com\/chem\/ (accessed Jul 29, 2023)."},{"key":"ref106\/cit106","doi-asserted-by":"publisher","DOI":"10.1081\/JLC-120003274"},{"key":"ref107\/cit107","unstructured":"FDA CDER\n                      Liquid Chromatography-High Resolution Mass\nSpectrometry\n(LC-HRMS) Method for the Determination of Six Nitrosamine Impurities\nin ARB Drugs\n                      . https:\/\/www.fda.gov\/media\/125478\/download (accessed Jan 17, 2025)."},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1039\/C8AY00014J"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2014.53037"},{"key":"ref110\/cit110","unstructured":"Ad-hoc projects of the OMCL Network - European Directorate for the\nQuality of Medicines & HealthCare\n                      . https:\/\/www.edqm.eu\/en\/ad-hoc-projects-of-the-omcl-network (accessed Jul 29, 2023)."},{"key":"ref111\/cit111","unstructured":"European Directorate for\nthe Quality of Medicines and Healthcare\n                      . https:\/\/www.edqm.eu\/en\/-\/new-omcl-method-for-simultaneous-determination-of-ndma-and-ndea-in-sartans-1 (accessed Jul 29, 2023)."},{"key":"ref112\/cit112","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2005.04.057"},{"key":"ref113\/cit113","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2016.07.014"},{"key":"ref114\/cit114","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2008.11.025"},{"key":"ref115\/cit115","doi-asserted-by":"publisher","DOI":"10.1021\/ac504104k"},{"key":"ref116\/cit116","doi-asserted-by":"publisher","DOI":"10.1007\/s10337-016-3040-1"},{"key":"ref117\/cit117","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9673(95)01073-4"},{"key":"ref118\/cit118","unstructured":"Accueil\u2212ANSM\n                      . https:\/\/ansm.sante.fr\/ (accessed\nJul 30, 2023)."},{"key":"ref119\/cit119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.04.035"},{"key":"ref120\/cit120","unstructured":"2021 News Update:\nNitrosamine Impurity Testing and Analysis, including\nN-nitrosodimethylamine (NDMA), in API and final drug products by LC-MS\/MS,\nGC-MS and GC-MS\/MS Methods\n                      . https:\/\/www.intertek.com\/pharmaceutical\/news\/nitrosodimethylamine-ndma-valsartan-drug-substance\/ (accessed Jul 30, 2023)."},{"key":"ref121\/cit121","doi-asserted-by":"publisher","DOI":"10.1021\/es3023094"},{"key":"ref122\/cit122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jes.2017.05.028"},{"key":"ref123\/cit123","unstructured":"Phenomenex UHPLC, HPLC, SPE, GC - Leader in Analytical\nChemistry\nSolutions\n                      . https:\/\/www.phenomenex.com\/ (accessed Jul 30, 2023)."},{"key":"ref124\/cit124","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2024.465399"},{"key":"ref125\/cit125","doi-asserted-by":"publisher","DOI":"10.1093\/jaoac\/84.5.1413"},{"key":"ref126\/cit126","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2013.06.070"},{"key":"ref127\/cit127","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2012.04.027"},{"key":"ref128\/cit128","doi-asserted-by":"publisher","DOI":"10.1021\/ac00096a008"},{"key":"ref129\/cit129","doi-asserted-by":"publisher","DOI":"10.1039\/C6AY01169A"},{"key":"ref130\/cit130","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.K3851"},{"key":"ref131\/cit131","first-page":"1","year":"2018","journal-title":"GC\/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance"},{"key":"ref132\/cit132","unstructured":"Kuddus, M.\n                      Analysis of the co-dispersion structure of health-related indicators, the center of the subject\u2019s sense of health, and the elderly people living at home\n                      , 2019; pp 1\u22127."},{"key":"ref133\/cit133","unstructured":"Ad-hoc projects of the OMCL Network - European Directorate\nfor the\nQuality of Medicines & HealthCare\n                      . https:\/\/www.edqm.eu\/en\/ad-hoc-projects-of-the-omcl-network (accessed\nJul 30, 2023)."},{"key":"ref134\/cit134","unstructured":"European Directorate for\nthe Quality of Medicines and Healthcare\n                      . https:\/\/www.edqm.eu\/en\/-\/new-omcl-method-for-simultaneous-determination-of-ndma-and-ndea-in-sartans-1 (accessed Jul 30, 2023)."},{"key":"ref135\/cit135","unstructured":"Development (Formulation,\nScale-up, Method Development): SHIMADZU\n(Shimadzu Corporation)\n                      . https:\/\/www.shimadzu.com\/an\/industries\/small-molecule-pharmaceutical\/development\/index.html (accessed Apr 29, 2024)."},{"key":"ref136\/cit136","unstructured":"Ames Test - Introduction,\nPrinciple, Procedure, Uses and Interpretation\n                      . https:\/\/microbiologyinfo.com\/ames-test\/ (accessed Apr 30, 2024)."},{"key":"ref137\/cit137","unstructured":"Ames Test - Principle,\nProcedure, Result, Limitation, Applications\n                      . https:\/\/microbiologynote.com\/ames-test-principle-procedure-result\/ (accessed Apr 30, 2024)."},{"key":"ref138\/cit138","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.2763"},{"key":"ref139\/cit139","doi-asserted-by":"publisher","DOI":"10.1006\/rwgn.2001.1543"},{"key":"ref140\/cit140","doi-asserted-by":"crossref","unstructured":"F\u00f6llmann, W.; Degen, G.; Oesch, F.; Hengstler, J.G.\n                      Ames Test, Brenner\u2019s Encyclopedia of Genetics\n                      , 2nd ed. Elsevier, 2013; pp 104\u2212107.","DOI":"10.1016\/B978-0-12-374984-0.00048-6"},{"key":"ref141\/cit141","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(00)00064-6"},{"key":"ref142\/cit142","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804667-8.00003-1"},{"key":"ref143\/cit143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.70.8.2281"},{"key":"ref144\/cit144","volume":"31","author":"EMA","year":"2019","journal-title":"EMA to review ranitidine medicines following detection of NDMA"},{"key":"ref145\/cit145","unstructured":"EMA\n                      EMA Sartan medicines: companies to review manufacturing\nprocesses to avoid presence of nitrosamine impurities\n                      ; European Medicines Agency, 2019; Vol. 44, pp 1\u22124."},{"key":"ref146\/cit146","first-page":"24","author":"Food and Drug Administration","year":"2021","journal-title":"Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry (Revision 1)"},{"key":"ref147\/cit147","author":"European Medicines Agency (EMA)","year":"2019","journal-title":"EMA update on metformin diabetes medicines"},{"key":"ref148\/cit148","unstructured":"News about GMP\/cGMP - GMP-Verlag: EMA: ICH Q13 on Continuous Manufacturing\nAdopted\n                      . https:\/\/www.gmp-publishing.com\/content\/en\/gmp-news\/news-about-gmp-cgmp\/d\/ema-ich-q13-on-continuous-manufacturing-adopted (accessed Apr 12, 2024)."},{"key":"ref149\/cit149","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60785-4"},{"key":"ref150\/cit150","unstructured":"Therapeutic\nGoods Administration\n(TGA) https:\/\/www.tga.gov.au\/node\/881814 (accessed Jul 30, 2023)."},{"key":"ref151\/cit151","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02120"},{"key":"ref152\/cit152","unstructured":"Nitrosocinacalcet Nitrosamine Impurity Triggers\nBig Recall From Dr.\nReddys, Accord\u2212Qvents\n                      . https:\/\/qvents.in\/nitrosocinacalcet-nitrosamine-ndsri-impurity-accord-dr-reddys-drl-recall-batches\/ (accessed Dec 24, 2024)."},{"key":"ref153\/cit153","unstructured":"FDA Updates Recall on\nBlood Pressure Medication Due to Possible Carcinogen\n- Nitrosamines in the News - Nitrosamines Exchange\n                      . https:\/\/nitrosamines.usp.org\/t\/fda-updates-recall-on-blood-pressure-medication-due-to-possible-carcinogen\/12149 (accessed Dec 24, 2024)."},{"key":"ref154\/cit154","unstructured":"Aurobindo, Glenmark, Zydus\nissue recalls for impurity and label issues\n                      . https:\/\/www.fiercepharma.com\/manufacturing\/aurobindo-glenmark-zydus-issue-recalls-impurity-and-label-issues (accessed Dec 24, 2024)."},{"key":"ref155\/cit155","unstructured":"Dr Reddy\u2019s Laboratories\nrecalls over 3.31 lakh bottles of\nCinacalcet tablets - CNBC TV18\n                      . https:\/\/www.cnbctv18.com\/market\/dr-reddy-laboratories-recalls-over-3-lakh-bottles-cinacalcet-tablets-shares-price-19503001.htm (accessed Dec 24, 2024)."},{"key":"ref156\/cit156","unstructured":"Assessment and Control\nOf Dna Reactive (Mutagenic) Impurities In\nPharmaceuticals to Limit Potential Carcinogenic Risk M7(R1) Current\nStep 4 version\n                      , 2017. https:\/\/www.ema.europa.eu\/en\/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-scientific-guideline (accessed Jan 17, 2025)."},{"key":"ref157\/cit157","author":"European Medicines Agency","journal-title":"ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Scientific guideline"},{"key":"ref158\/cit158","unstructured":"US-FDA NDSRI Limits update\n-Mar 2024 - Limits of Nitrosamines - Nitrosamines\nExchange\n                      . https:\/\/nitrosamines.usp.org\/t\/fda-ndsri-limits-update-mar-2024\/9463 (accessed May 2, 2024)."},{"key":"ref159\/cit159","unstructured":"CA Health Canada updated\nthe guidance and Appendix 1(March 15, 2024)\n- Limits of Nitrosamines - Nitrosamines Exchange\n                      . https:\/\/nitrosamines.usp.org\/t\/health-canada-updated-the-guidance-and-appendix-1-march-15-2024\/9541 (accessed May 2, 2024)."},{"key":"ref160\/cit160","unstructured":"Questionnaire for Excipient\nNitrosamines Risk Evaluation Comparison\nQuestionnaire For Excipient\n                      . www.ipec-europe.org (accessed\nApr 30, 2024)."},{"key":"ref161\/cit161","author":"Active Pharmaceutical Ingredients Committee (APIC)","journal-title":"Additional guidance on the assessment on the risk assessment for presence of N-nitrosamines in APIs"},{"key":"ref162\/cit162","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00118"},{"key":"ref163\/cit163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113425"},{"key":"ref164\/cit164","unstructured":"Workflows for Quality risk management of nitrosamine risks\nin medicines\n                      , 2022. https:\/\/www.efpia.eu\/media\/676632\/efpia-nitrosamines-quality-risk-management-workflows-sep-2022.pdf (accessed Aug 27, 2024)."},{"key":"ref165\/cit165","unstructured":"Workflows for Quality\nrisk management of nitrosamine risks in medicines\n                      , 2020. https:\/\/www.efpia.eu\/media\/580594\/workflows-for-quality-risk-management-of-nitrosamine-risks-in-medicines.pdf (accessed Aug 27, 2024)."},{"key":"ref166\/cit166","unstructured":"Nitrosamine Impurities\nin Pharmaceuticals: Challenges and Solutions\n                      . https:\/\/pharmaknowledgeforum.com\/nitrosamine-impurities-in-pharmaceuticals-challenges-and-solutions\/?form=MG0AV3 (accessed Dec 7, 2024)."},{"key":"ref167\/cit167","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02523-w"},{"key":"ref168\/cit168","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.04.016"},{"key":"ref169\/cit169","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac164"},{"key":"ref170\/cit170","unstructured":"6 Steps to reduce\nnitrosamines impurities in Pharma industry - Zamann\nPharma Support GmbH\n                      . https:\/\/zamann-pharma.com\/2024\/08\/05\/6-steps-to-reduce-nitrosamines-impurities-in-pharma-industry\/ (accessed Dec 7, 2024)."},{"key":"ref171\/cit171","unstructured":"Role of Big Data in Nitrosamine\nRisk Assessment - Zamann Pharma Support\nGmbH\n                      . https:\/\/zamann-pharma.com\/2024\/07\/26\/the-role-of-big-data-in-nitrosamine-risk-assessment\/?form=MG0AV3 (accessed Dec 7, 2024)."},{"key":"ref172\/cit172","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-013-9644-8"},{"key":"ref173\/cit173","volume-title":"Schr\u00f6dinger Release 2021\u22124; Protein Preparation Wizard","year":"2021"},{"key":"ref174\/cit174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184331"},{"key":"ref175\/cit175","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1847197"},{"key":"ref176\/cit176","doi-asserted-by":"publisher","DOI":"10.24966\/PMRR-0177\/100018"},{"key":"ref177\/cit177","first-page":"17","volume":"19","author":"Majid N.","year":"2023","journal-title":"Malays. J. Med. Health Sci."},{"key":"ref178\/cit178","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/17.9.2029"},{"key":"ref179\/cit179","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-022-03347-6"},{"key":"ref180\/cit180","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2011.09.010"},{"key":"ref181\/cit181","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105730"},{"key":"ref182\/cit182","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186"},{"key":"ref183\/cit183","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202100435"},{"key":"ref184\/cit184","author":"Biba E.","year":"2020","journal-title":"General chapter <1469> nitrosamine impurities"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.4c01173","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.4c01173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:10:35Z","timestamp":1756714235000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.4c01173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":184,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["10.1021\/acs.molpharmaceut.4c01173"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01173","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}